Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

J Immunother Cancer. 2020 Dec;8(2):e001235. doi: 10.1136/jitc-2020-001235.


The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.

Keywords: antineoplastic protocols; guidelines as topic; hematologic neoplasms; immunotherapy.

MeSH terms

  • Female
  • Guidelines as Topic / standards*
  • Humans
  • Immunotherapy / methods*
  • Lymphoma / drug therapy*
  • Male